Equities Analysts Offer Predictions for I-Mab Q3 Earnings

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for I-Mab from ($0.09) to ($0.05), maintaining a "Buy" rating and a price target of $7.00.
• I-Mab reported a quarterly earnings of ($0.07), exceeding analysts’ expectations of ($0.10), which indicates better-than-anticipated performance.
• Several institutional investors have increased their stakes in I-Mab, reflecting growing interest, with 38.38% of the stock now owned by such investors.

I-Mab Sponsored ADR (NASDAQ:IMAB - Free Report) - Investment analysts at HC Wainwright lifted their Q3 2025 earnings per share estimates for shares of I-Mab in a research report issued on Thursday, August 21st. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.05) for the quarter, up from their previous forecast of ($0.09). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for I-Mab's current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for I-Mab's Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.23) EPS, FY2026 earnings at ($0.62) EPS, FY2027 earnings at ($0.69) EPS, FY2028 earnings at ($0.74) EPS and FY2029 earnings at ($0.53) EPS.

IMAB has been the subject of a number of other research reports. Wall Street Zen upgraded I-Mab from a "hold" rating to a "buy" rating in a research note on Saturday, August 23rd. Loop Capital set a $8.00 price target on I-Mab in a research note on Thursday. Brookline Capital Management reiterated a "buy" rating on shares of I-Mab in a research note on Thursday. Finally, Needham & Company LLC lifted their price target on I-Mab from $5.00 to $6.00 and gave the company a "buy" rating in a research note on Wednesday, August 20th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $7.00.

I-Mab Price Performance

IMAB stock traded down $0.09 during mid-day trading on Monday, reaching $4.16. 1,401,885 shares of the company traded hands, compared to its average volume of 4,858,753. I-Mab has a fifty-two week low of $0.60 and a fifty-two week high of $5.90. The firm's 50 day moving average price is $3.03 and its 200 day moving average price is $1.77.

I-Mab (NASDAQ:IMAB - Get Free Report) last released its quarterly earnings results on Wednesday, August 20th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.03.

Institutional Investors Weigh In On I-Mab

A number of hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC raised its holdings in shares of I-Mab by 6.6% in the 2nd quarter. SG Americas Securities LLC now owns 876,353 shares of the company's stock worth $2,121,000 after purchasing an additional 54,312 shares during the period. Stonepine Capital Management LLC bought a new stake in shares of I-Mab in the 1st quarter worth approximately $398,000. Cantor Fitzgerald L. P. bought a new stake in shares of I-Mab in the 4th quarter worth approximately $119,000. BNP Paribas Financial Markets bought a new stake in shares of I-Mab in the 4th quarter worth approximately $93,000. Finally, Millennium Management LLC raised its holdings in shares of I-Mab by 763.1% in the 4th quarter. Millennium Management LLC now owns 97,749 shares of the company's stock worth $83,000 after purchasing an additional 86,424 shares during the period. Institutional investors own 38.38% of the company's stock.

I-Mab Company Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.